Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for Decompensated Cirrhosis (MSC-DLC-1b)
NCT05984303Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord derived mesenchymal stem cells in decompensated cirrhosis (2 cohorts), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Incidence of Adverse Events at 28 days, Incidence of dose-limiting toxicity-related adverse events at 28 days and 2 more. Status: unknown.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on NCT05984303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984303.